Breast cancer (AKT pathway gene testing (PIK3CA, AKT1, PTEN) [Tissue]

Three mock clinical cases with matching patient or artificial FFPE (designed to simulate real patient samples). One 10um or  15um FFPE section per case is provided.

Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
 
Variant allele frequencies of the artificial FFPE reference materials have been validated using ddPCR. 

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Restricted to 120 participants, please register early to avoid disappointment. Open to laboratories from ALL countries (note: some restrictions may apply*)

This EQA is supported by an educational grant from AstraZeneca, fees are subsidised so there is a reduced cost for participants. EMQN would like to acknowledge and thank AstraZeneca for this support.

*Sanctions, delivery network exceptions, restrictions on importation etc.